Immunoallergic drug-induced hepatitis: Lessons from halothane

Journal of Hepatology, Supplement

Volumn 26, Issue 1, 1997, Pages 5-12

  Kenna, J Gerald ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Bioactivation; Cytochrome P450; Drug hepatotoxicity; Protein adducts; Volatile anaesthetics

Indexed keywords

HALOTHANE;

ANIMAL; BIOTRANSFORMATION; HUMAN; IMMUNOLOGY; LIVER; LYMPHOCYTE; PATHOLOGY; REVIEW; TOXIC HEPATITIS;

ANIMALS; BIOTRANSFORMATION; HALOTHANE; HEPATITIS, TOXIC; HUMANS; LIVER; LYMPHOCYTES;

EID: 0030629505     PISSN: 01695185     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Pessayre D. Mechanisms of drug-induced hepatic injury. In: Stricker BHC, ed. Drug Induced Hepatic Injury, 2nd edn. Amsterdam: Elsevier, 1992: 23-49.
2. Kenna JG, van Pelt FNAM. The metabolism and toxicity of inhaled anaesthetic agents. Anaesth Pharm Rev 1994; 2: 29-42.
3. Walton B, Simpson BR, Strunin L, Doniach D, Perrin J, Appleyard AJ. Unexplained hepatitis following halothane. Br Med J 1976; 1: 1171-6.
4. Kenna JG, Neuberger JM. Immunopathogenesis and treatment of halothane hepatitis. Clin Immunother 1995; 3: 108-24.
5. Vergani D, Tsantoulas D, Eddleston ALWF, Davis M, Williams R. Sensitization to halothane-altered liver components in severe hepatic necrosis after halothane anaesthesia. Lancet 1978; ii: 801-3.
6. Vergani D, Mieli-Vergani G, Alberti A, Neuberger J, Eddleston ALWF, Davis M, Williams R. Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med 1980; 303: 66-71.
7. Kenna JG, Neuberger J, R. W. Identification by immunoblotting of three halothane-induced liver microsomal polypeptide antigens recognized by antibodies in sera from patients with halothane-associated hepatitis. J Pharmacol Exp Ther 1987; 242: 733-40.
8. Kenna JG, Neuberger J, Williams R. Evidence for expression in human liver of halothane-induced neoantigens recognized by antibodies in sera from patients with halothane hepatitis. Hepatology 1988; 8: 1635-41.
9. Kenna JG, Satoh H, Christ DD, L. R. P. Metabolic basis for a drug hypersensitivity: antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane. J Pharmacol Exp Ther 1988; 245: 1103-9.
10. van Pelt FNAM, Kenna JG. Formation of trifluoroacetylated protein antigens in cultured rat hepatocytes exposed to halothane in vitro. Biochem Pharmacol 1994; 48: 461-71.
11. Harris JW, Pohl LR, Martin JL, Anders MW. Tissue acylation by the chlorofluorocarbon substitute 2,2-dichloro-1,1,1-trifluoroethane. Proc Natl Acad Sci USA 1991; 88: 1407-10.
12. Kenna JG, Martin JL, Pohl LR. The topography of trifluoroacetylated protein antigens in liver microsomal fractions from halothane treated rats. Biochem Pharmacol 1992; 44: 621-9.
13. Knight TL, Scatchard KM, van Pelt FNAM, Kenna JG. Sera from patients with haliothane hepatitis contain antibodies to halothane-induced liver antigens which are not detectable by immunoblotting. J Pharmacol Exp Ther 1994; 270: 1325-33.
14. Kharasch ED, Hankins D, Mautz D, Thummel KE. Identification of the enzyme responsible for oxidative halothane metabolism: implications for prevention of halothane hepatitis. Lancet 1996; 18: 1367-71.
15. Eliasson E, Kenna JG. Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis. Mol Pharmacol 1996; 50: 573-82.
16. Kenna JG, Martin JL, Satoh H, Pohl LR. Factors affecting the expression of trifluoroacetylated liver microsomal protein neoantigens in rats treated with halothane. Drug Metab Dispos 1990; 18: 788-93.
17. Bourdi M, Chen W, Peter RM, Martin JL, Buters JTM, Nelson SD, Pohl LR. Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. Chem Res Toxicol 1996; 9: 1159-66.
18. O'Shea D, Davis SN, Kim RB, Wilkinson GR. Effect of fasting and obesity on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther 1994; 56: 359-67.
19. Pohl LR, Thomassen D, Pumford NR, Butler LE, Satoh H, Ferrans VJ, Perrone A, Martin BM, Martin JL. Hapten carrier conjugates associated with halothane hepatitis. In: Witmer C, Snyder R, Jollow D, KaIf G, Kocsis J, Sipes I, eds. Bological Reactive Intermediates IV. New York: Plenum Press, 1990: 111-20.
20. Kitteringham NR, Kenna JG, Park BK. Detection of autoantibodies directed against human hepatic endoplasmic reticulum in sera from patients with halothane hepatitis. Br J Clin Pharmacol 1995; 40: 379-86.
21. Smith GCM, Kenna JG, Harrison DJ, Tew D, Wolf CR. Autoantibodies to hepatic microsomal carboxylesterase in halothane hepatitis. Lancet 1993; 342: 963-4.
22. Park BK, Kitteringham NR. Drug-protein conjugation and its immunological consequences. Drug Metab Rev 1990; 22: 87-144.
23. Christen U, Jeno P, Gut J. Halothane metabolism: the dihydrolipoamide acetyltransferase subunit of the pyruvate dehydrogenase complex molecularly mimics trifluoroacetyl-protein adducts. Biochemistry 1993; 32: 1492-9.
24. Frey N, Christen U, Jeno P, Yeaman SJ, Shimomura Y, Kenna JG, Gandolfi AJ, Ranek L, Gut J. The lipoic acid containing components of the 2-oxoacid dehydrogenase complexes mimic trifluoroacetylated proteins and are autoantigens associated with halothane hepatitis. Chem Res Toxicol 1995; 8: 736-46.
25. Gut J, Christen U, Huwyler J, Bürgin M, Kenna J. Molecular mimicry of trifluoroacetylated human liver protein adducts by constitutive proteins and immunochemical evidence for its impairment in halothane hepatitis. Eur J Biochem 1992; 210: 569-76.
26. Pelham HRB. The retention signal for soluble proteins of the endoplasmic reticulum. Trends Biochem Sci 1990; 15: 483-6.
27. Lewis JH, Zimmerman HJ, Ishak KG, Mullick FG. Enflurane hepatotoxicity. A clinicopathologic study of 24 cases. Ann Intern Med 1983; 98: 984-92.
28. Zimmerman HJ. Even isoflurane. Hepatology 1991; 13: 1251-3.
29. Christ DD, Kenna JG, Kammerer W, Satoh H, Pohl LR. Enflurane metabolism produces covalently bound liver adducts recognized by antibodies from patients with halothane hepatitis. Anesthesiology 1988; 69: 833-8.
30. Christ DD, Satoh H, Kenna JG, Pohl LR. Potential metabolic basis for enflurane hepatitis and the apparent cross-sensitization between enflurane and halothane. Drug Metab Dispos 1988; 16: 135-40.
31. Koskinas J, Kenna JG, Bird GL, Alexander GJM, Williams R. Immunoglobulin A antibody to a 200-kilodalton cytosolic acetaldehyde adduct in alcoholic hepatitis. Gastroenterology 1992; 103: 1860-7.
32. Clot P, Albano E, Eliasson E, Tabone M, Arico S, Israel Y, Moncada C, Ingelman-Sundberg M. Cytochrome P4502E1 hydroxyethyl radical adducts as the major antigen in autoantibody formation among alcoholics. Gastroenterology 1996; 111: 206-16.
33. Neuberger J, Kenna JG, Aria KN, Williams R. Antibody mediated hepatocyte injury in methyl dopa induced hepatotoxicity. Gut 1985; 26: 1233-9.
34. Neuberger J, Williams R. Immune mechanisms in tienilic acid associated hepatotoxicity. Gut 1989; 30: 515-9.
35. Beaune PH, Dansette PM, Mansuy D, Kiffel L, Finck M, Amar C, Leroux JP, Homberg JC. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci USA 1987; 84: 551-5.
36. Bourdi M, Larrey D, Nataf J, Bernuau J, Pessayre D, Iwasaki M, Guengerich FP, Beaune PH. Anti-liver endoplasmic reticulum autaontibodies are directed against human cytochrome P-4501A2. A specific marker of dihydralazine-induced hepatitis. J Clin Invest 1990; 85: 1967-73.
37. Uetrecht JP. The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions. Drug Metab Rev 1992; 24: 299-366.
38. Satoh H, Fukuda Y, Anderson DK, Ferrans VJ, Gillette JR, Pohl LR. Immunological studies on the mechanism of halothane-induced hepatotoxicity: immunohistochemical evidence of trifluoroactylated hepatocytes. J Pharmacol Exp Ther 1985; 233: 857-62.
39. Pohl LR. An immunochemical approach of identifying and characterizing protein targets of toxic reactive metabolites. Chem Res Toxicol 1993; 6: 786-93.
40. Kenna JG, Jones RM. The organ toxicity of inhaled anesthetics. Anesth Analg 1995; 81: S51-66.
41. Martin JL, Plevak DJ, Flannery KD, Charlton M, Poterucha JJ, Humphreys CE, Derfus G, Pohl LR. Hepatotoxicity after desflurane anesthesia. Anesthesiology 1995; 83: 1125-9.
42. Boelsterli UA, Zimmerman HJ, Kretz-Rommel A. Idiosyncratic liver toxicity of nonsteroidal antiinflammatory drugs: molecular mechanisms and pathology. Crit Rev Toxicol 1995; 25: 207-35.
43. Thomassen D, Martin BM, Martin JL, Pumford NR, Pohl LR. The role of a stress protein in the development of a drug-induced allergic response. Eur J Pharmacol 1990; 183: 1138-9.
44. Davila JC, Martin BM, Pohl LR. Patients with halothane hepatitis have serum antibodies directed against glucose-regulated stress protein GRP78/BiP. Toxicologist 1992; 12: 255.
45. Pumford NR, Martin BM, Thomassen D, Burris JA, Kenna JG, Martin JL, Pohl LR. Serum antibodies from halothane hepatitis patients react with the endoplasmic reticulum protein ERp72. Chem Res Toxicol 1993; 6: 609-15.
46. Butler LE, Thomassen D, Martin JL, Martin BM, Kenna JG, Pohl LR. The calcium binding protein calreticulin is covalently modified in rat liver by a reactive metabolite of the inhalation anesthetic halothane. Chem Res Toxicol 1992; 5: 406-10.
47. Satoh H, Martin BM, Schulick AH, Christ DD, Kenna JG, Pohl LR. Human anti-endoplasmic reticulum antibodies in sera of patients with halothane-induced hepatitis are directed against a trifluoroacetylated carboxylesterase. Proc Natl Acad Sci USA 1989; 86: 322-6.
48. Martin JL, Pumford NR, LaRosa AC, Martin BM, Gonzaga HMS, Beaven MA, Pohl LR. A metabolite of halothane covalently binds to an endoplasmic reticulum protein that is highly homologous to phosphatidylinositol-specific phospholipase C-α but has no activity. Biochem Biophys Res Commun 1991; 178: 679-85.
49. Martin JL, Kenna JG, Martin BM, Thomassen D, Reed GF, Pohl LR. Halothane hepatitis patients have serum antibodies that react with protein disulfide isomerase. Hepatology 1993; 18: 858-63.